EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA)

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide, commonly known as AB-CHMINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.